Antitumor activity of TNF-α after intratumoral injection using an in situ thermosensitive hydrogel

References

• Wolinsky JB, Colson YL, Grinstaff MW. Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. J Control Release 2012;159:14–26
   PubMed Web of Science ®Google Scholar
• Bhattarai N, Gunn J, Zhang M. Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Deliv Rev 2010;62:83–99
   PubMed Web of Science ®Google Scholar
• Elstad NL, Fowers KD. OncoGel (ReGel/paclitaxel)-clinical applications for a novel paclitaxel delivery system. Adv Drug Deliv Rev 2009;61:785–94
   PubMed Web of Science ®Google Scholar
• Vermonden T, Censi R, Hennink WE. Hydrogels for protein delivery. Chem Rev 2012;112:853–88
   Web of Science ®Google Scholar
• Huynh CT, Nguyen MK, Lee DS. Injectable block copolymer hydrogels: achievements and future challenges for biomedical applications. Macromolecules 2011;44:6629–36
   Web of Science ®Google Scholar
• Carswell E, Old LJ, Kassel R, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666–70
   PubMed Web of Science ®Google Scholar
• Roberts NJ, Zhou S, Diaz LA Jr, et al. Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget 2011;2:739–51
   PubMedGoogle Scholar
• Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin 2008;29:1275–88
   PubMed Web of Science ®Google Scholar
• Kroon HM, Thompson JF. Isolated limb infusion: a review. J Surg Oncol 2009;100:169–77
   PubMed Web of Science ®Google Scholar
• Tabata Y, Uno K, Ikada Y, et al. Suppressive effect of recombinant TNF-gelatin conjugate on murine tumour growth in-vivo. J Pharm Pharmacol 1993;45:303–8
   PubMed Web of Science ®Google Scholar
• Kamada H, Tsutsumi Y, Yamamoto Y, et al. Antitumor activity of tumor necrosis factor-α conjugated with polyvinylpyrrolidone on solid tumors in mice. Cancer Res 2000;60:6416–20
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Kihira T, Yamamoto S, et al. Chemical modification of natural human tumor necrosis factor-α with polyethylene glycol increases its antitumor potency. Cancer Sci 1994;85:9–12
   Google Scholar
• Jiang Y-Y, Liu C, Hong M-H, et al. Tumor cell targeting of transferrin-PEG-TNF-α conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation. Bioconjug Chem 2007;18:41–9
   PubMed Web of Science ®Google Scholar
• Dai C, Fu Y, Chen S, et al. Preparation and evaluation of a new releasable PEGylated tumor necrosis factor-α (TNF-α) conjugate for therapeutic application. Sci China Life Sci 2013;56:51–8
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Tsutsumi Y, Yoshioka Y, et al. Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity. Nat Biotechnol 2003;21:546–52
   PubMed Web of Science ®Google Scholar
• Shibata H, Yoshioka Y, Ikemizu S, et al. Functionalization of tumor necrosis factor-α using phage display technique and PEGylation improves its antitumor therapeutic window. Clin Cancer Res 2004;10:8293–300
   PubMed Web of Science ®Google Scholar
• Jang S-H, Kim H, Cho K-H, et al. Development of human tumor necrosis factor-α muteins with improved therapeutic potential. BMB Reports 2009;42:260–4
   PubMed Web of Science ®Google Scholar
• Curnis F, Sacchi A, Borgna L, et al. Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000;18:1185–90
   PubMed Web of Science ®Google Scholar
• Borsi L, Balza E, Carnemolla B, et al. Selective targeted delivery of TNFα to tumor blood vessels. Blood 2003;102:4384–92
   PubMed Web of Science ®Google Scholar
• Curnis F, Gasparri A, Sacchi A, et al. Coupling tumor necrosis factor-α with αV integrin ligands improves its antineoplastic activity. Cancer Res 2004;64:565–71
   PubMed Web of Science ®Google Scholar
• Balza E, Mortara L, Sassi F, et al. Targeted delivery of tumor necrosis factor-α to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin Cancer Res 2006;12:2575–82
   PubMed Web of Science ®Google Scholar
• Bauer S, Adrian N, Fischer E, et al. Structure-activity profiles of Ab-derived TNF fusion proteins. J Immunol 2006;177:2423–30
   PubMed Web of Science ®Google Scholar
• Krippner-Heidenreich A, Grunwald I, Zimmermann G, et al. Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity. J Immunol 2008;180:8176–83
   PubMed Web of Science ®Google Scholar
• Wang H, Chen K, Cai W, et al. Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein. Mol Cancer Ther 2008;7:1044–53
   PubMed Web of Science ®Google Scholar
• Burton ER, Libutti SK. Targeting TNF-α for cancer therapy. J Biol 2009;8:1–5
   Google Scholar
• Chen B, Cao S, Zhang Y, et al. A novel peptide (GX1) homing to gastric cancer vasculature inhibits angiogenesis and cooperates with TNF alpha in anti-tumor therapy. BMC Cell Biol 2009;10:63
   PubMed Web of Science ®Google Scholar
• Gerspach J, Pfizenmaier K, Wajant H. Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects. Biofactors 2009;35:364–72
   PubMed Web of Science ®Google Scholar
• Yuan X, Lin X, Manorek G, et al. Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. Mol Cancer Ther 2009;8:1906–15
   PubMed Web of Science ®Google Scholar
• Crescenzi M, Persano L, Esposito G, et al. Vandetanib improves anti-tumor effects of L19mTNFα in xenograft models of esophageal cancer. Clin Cancer Res 2011;17:447–58
   PubMed Web of Science ®Google Scholar
• Calcinotto A, Grioni M, Jachetti E, et al. Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J Immunol 2012;188:2687–94
   PubMed Web of Science ®Google Scholar
• Li Y-P, Pei Y-Y, Zhou Z-H, et al. PEGylated polycyanoacrylate nanoparticles as tumor necrosis factor-α carriers. J Control Release 2001;71:287–96
   PubMed Web of Science ®Google Scholar
• Visaria RK, Griffin RJ, Williams BW, et al. Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor-α delivery. Mol Cancer Ther 2006;5:1014–20
   PubMed Web of Science ®Google Scholar
• Messerschmidt SK, Musyanovych A, Altvater M, et al. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells. J Control Release 2009;137:69–77
   PubMed Web of Science ®Google Scholar
• Libutti SK, Paciotti GF, Byrnes AA, et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 2010;16:6139–49
   PubMed Web of Science ®Google Scholar
• Xu Y, Shen Y, Xiong Y, et al. Synthesis, characterization, biodegradability and biocompatibility of a temperature-sensitive PBLA-PEG-PBLA hydrogel as protein delivery system with low critical gelation concentration. Drug Dev Ind Pharm 2013. [Epub ahead of print]. doi:10.3109/03639045.2013.814066
   Web of Science ®Google Scholar
• Zhang Y, Huo M, Zhou J, et al. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Meth Prog Bio 2010;99:306–14
   PubMed Web of Science ®Google Scholar
• Ferraiolo B, Moore J, Crase D, et al. Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-α in mice. Drug Metab Dispos 1988;16:270–5
   PubMed Web of Science ®Google Scholar
• Yang J, Li L, Yongjie W, et al. Pharmacokinetics study of novel recombinant human tumor necrosis factor-α in mice using ELISA. Chinese Pharmacological Bulletin 2005;7:847–51
   Google Scholar
• Liu H, Xu H, Wang Y, et al. Effect of intratumoral injection on the biodistribution and therapeutic potential of novel chemophor EL-modified single-walled nanotube loading doxorubicin. Drug Dev Ind Pharm 2012;38:1031–8
   PubMed Web of Science ®Google Scholar
• Kang YM, Kim GH, Kim JI, et al. In vivo efficacy of an intratumorally injected in situ-forming doxorubicin/poly (ethylene glycol)-b-polycaprolactone diblock copolymer. Biomaterials 2011;32:4556–64
   PubMed Web of Science ®Google Scholar
• Al-Abd AM, Hong K-Y, Song S-C, et al. Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice. J Control Release 2010;142:101–7
   PubMed Web of Science ®Google Scholar